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High-grade serous ovarian cancer 
cell lines exhibit heterogeneous responses 
to growth factor stimulation
Danielle L. Bourgeois, Karl A. Kabarowski, Veronica L. Porubsky and Pamela K. Kreeger*
Abstract 
Background: The factors driving the onset and progression of ovarian cancer are not well understood. Recent 
reports have identified cell lines that are representative of the genomic pattern of high-grade serous ovarian cancer 
(HGSOC), in which greater than 90 % of tumors have a mutation in TP53. However, many of these representative cell 
lines have not been widely used so it is unclear if these cell lines capture the variability that is characteristic of the 
disease.
Methods: We investigated six TP53-mutant HGSOC cell lines (Caov3, Caov4, OV90, OVCA432, OVCAR3, and OVCAR4) 
for migration, MMP2 expression, proliferation, and VEGF secretion, behaviors that play critical roles in tumor pro-
gression. In addition to comparing baseline variation between the cell lines, we determined how these behaviors 
changed in response to four growth factors implicated in ovarian cancer progression: HB-EGF, NRG1β, IGF1, and HGF.
Results: Baseline levels of each behavior varied across the cell lines and this variation was comparable to that seen in 
tumors. All four growth factors impacted cell proliferation or VEGF secretion, and HB-EGF, NRG1β, and HGF impacted 
wound closure or MMP2 expression in at least two cell lines. Growth factor-induced responses demonstrated sub-
stantial heterogeneity, with cell lines sensitive to all four growth factors, a subset of the growth factors, or none of 
the growth factors, depending on the response of interest. Principal component analysis demonstrated that the data 
clustered together based on cell line rather than growth factor identity, suggesting that response is dependent on 
intrinsic qualities of the tumor cell rather than the growth factor.
Conclusions: Significant variation was seen among the cell lines, consistent with the heterogeneity of HGSOC.
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Background
Ovarian cancer is the deadliest gynecological cancer in 
the developed world, with nearly two-thirds of patients 
diagnosed with advanced, metastatic disease [1]. Most 
of these patients initially respond to standard treatment 
of surgical debulking and chemotherapy, but over 70  % 
exhibit disease recurrence and eventual chemoresistance. 
High-grade serous ovarian cancer (HGSOC), a subtype 
characterized by a mutation in TP53, a low rate of other 
mutations, and extensive DNA copy number changes, is 
the most aggressive and most common subtype of ovar-
ian cancer, accounting for two-thirds of deaths [2, 3]. 
Due to the limited animal models that mimic the dis-
ease [4, 5], HGSOC has been primarily studied in  vitro 
and through xenograft models with cell lines. However, 
a recent analysis of ovarian cancer cell lines in the Can-
cer Cell Line Encyclopedia (CCLE) indicated that the 
most commonly used cellular models of HGSOC (i.e., 
SKOV3 and A2780) do not mimic the genomic charac-
teristics of tumors in The Cancer Genome Atlas (TCGA) 
database and suggested that future research should use 
more representative lines to develop improved treatment 
strategies [6]. Extensive patient-to-patient variation is 
observed within the HGSOC subtype; therefore, it will be 
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important to determine if limiting studies to these rep-
resentative lines can recapitulate this heterogeneity. To 
address this question, we performed the first comprehen-
sive study of representative HGSOC cell lines to examine 
the variation in their baseline and growth factor-induced 
behaviors with respect to processes that are important in 
metastasis.
Unlike other solid tumors, ovarian cancer is not 
restricted to metastasis through the blood and lymph 
systems; instead, tumor cells can exfoliate from the ovary 
and attach to organs in the peritoneum, especially the 
omentum [7]. This peritoneal metastasis is a complex 
process that relies on many different cellular actions, 
including migration, extracellular matrix remodeling, pro-
liferation, and angiogenesis. Tumor cell migration is a key 
step for dissemination of the tumor along the peritoneum 
[8], and has been modeled in vitro using two-dimensional 
cell migration assays. In addition to this mechanism of 
spreading, ovarian cancer cells can detach, transport 
through the peritoneal fluid and attach to new metastatic 
sites. The attachment of these cells into their new sites is 
mediated in part by matrix-metalloproteinase-2 (MMP2) 
[9]; MMP2 is also responsible for invasion of the tumor 
deeper into the tissue [10]. Studies have found that MMP2 
levels in ascites fluid increase in advanced stage ovarian 
cancer [11] and overexpression of MMP2 in peritoneal 
implants correlates with elevated mortality risk [12]. Fol-
lowing implantation and invasion, continued growth and 
viability of the tumors is maintained through cell pro-
liferation and angiogenesis. Not surprisingly, advanced 
stages of ovarian cancer and mortality risk are both asso-
ciated with high rates of proliferation [13]. As in other 
solid tumors, angiogenesis in ovarian cancer is mediated 
by the production of angiogenic factors such as vascular 
endothelial growth factor (VEGF) that recruit new vessels 
from the native vasculature [14–16].
The different stages of HGSOC metastasis are influ-
enced by the presence of growth factors and cytokines in 
the tumor microenvironment, which in HGSOC includes 
ascites fluid. For example, heparin-binding EGF-like 
growth factor (HB-EGF), neuregulin-1 beta (NRG1β), 
insulin-like growth factor 1 (IGF1), and hepatocyte growth 
factor (HGF) are all expressed in tumors and found at 
higher levels in ascites fluid of ovarian cancer patients 
compared to healthy controls [17–21]. Elevated HB-EGF 
expression has been associated with shorter progression-
free survival [22]; HB-EGF treatment induced invasion 
and VEGF production by SKOV3 in  vitro and promoted 
peritoneal dissemination of xenografts [23]. Autocrine 
NRG1β increased cell growth and decreased survival time 
in several xenograft mouse models of ovarian cancer [21]. 
Overexpression of IGF1 was associated with shorter pro-
gression-free survival [24] and has been shown to increase 
proliferation of OVCAR3 in vitro [25]. Elevated serum lev-
els of HGF were exhibited in >90 % of tumors and corre-
lated to shorter overall survival of ovarian cancer patients 
[26]. In vitro, HGF mediated an epithelial-to-mesenchymal 
transition and sustained anchorage-independent growth 
of ovarian cancer cells [27, 28].
Therefore, to determine if HGSOC cell lines that have 
genomic profiles similar to TCGA tumors (Caov3, Caov4, 
OV90, OVCA432, OVCAR3, OVCAR4) demonstrate 
heterogeneity in the various metastatic processes, we 
examined migration, MMP2 expression, proliferation, 
and VEGF secretion in response to HB-EGF, NRG1β, 
IGF1, and HGF.
Results
Tumor cell migration in response to growth factors varied 
across HGSOC cell lines
Progression in HGSOC is marked by the dissemina-
tion of tumor cells throughout the peritoneum [8], with 
tumor cells present as both single cells and as aggre-
gates [29]. Therefore, to model the behavior of these dif-
ferent cellular presentations, collective cell migration 
was examined by wound assays and single cell motility 
was modeled utilizing transwell assays. In the wound 
assays, we determined that all six cell lines migrated in 
the absence of stimulatory factors and that the extent 
of wound closure varied across the cell lines, ranging 
from 7.6 % for OVCAR3 to 41.4 % for OVCAR4 (Fig. 1). 
Following growth factor treatment, we observed that 
HGSOC cell lines had significantly increased migra-
tion after treatment with (1) three of the growth factors 
(Caov4, OVCAR3), (2) one of the growth factors (Caov3, 
OVCA432, OVCAR4), or (3) none of the tested growth 
factors (OV90). Overall, Caov4 and OVCAR3 had the 
most similar response, with increased migration when 
treated with HB-EGF, NRG1β, or HGF; however, Caov4 
had consistently greater wound closure. With respect 
to the individual growth factors, HGF had the broadest 
effect, with increased migration in Caov4, OVCA432, 
OVCAR3, and OVCAR4. Caov3, Caov4, and OVCAR3 
all had increased wound closure when treated with HB-
EGF, while only Caov4 and OVCAR3 were sensitive to 
NRG1β treatment. None of the cell lines studied exhib-
ited increased wound closure after IGF1 treatment.
Not surprisingly given the different biological mecha-
nisms involved [30], differences in migration were 
observed between the wound and transwell assays. In 
contrast to the variability seen with wound closure, 
most of the cell lines exhibited minimal levels of baseline 
migration through transwells (Fig. 2). In addition, Caov4, 
OV90, OVCAR3, and OVCAR4 were unresponsive to 
all of the tested growth factors. Caov3 and OVCA432 
had increased migration in response to HB-EGF, and 
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OVCA432 was also sensitive to NRG1β. Consistent with 
the wound assay, IGF1 did not impact migration for any 
of the cell lines in the transwell assay. Interestingly, none 
of the cell lines had increased migration in response to 
HGF in transwell assays, despite HGF impacting wound 
closure in four of the cell lines (Fig. 1).
MMP levels varied across HGSOC cell lines
MMPs are a critical component of metastasis in solid 
tumors, enabling the degradation and remodeling of 
extracellular matrix as tumor cells invade through the 
basement membrane and stroma [31]. To examine vari-
ation in the remodeling characteristics of these HGSOC 
cells, conditioned media was first assayed to characterize 
the total level of MMPs secreted by the cell panel in the 
absence of growth factor stimulation (Fig. 3a). OV90 had 
the lowest levels of MMPs and OVCAR3 the highest lev-
els. MMP2 has been shown to play a major role in medi-
ating ovarian cancer cell attachment to the omentum 
and enabling tumor cells to invade through the extra-
cellular matrix to establish further metastases [9, 10]. 
Therefore, we next examined the expression of MMP2 
and found that all of the cell lines had detectable levels 
(Fig.  3). Following growth factor treatment, cells had 
altered MMP2 levels in response to (1) two growth fac-
tors (Caov4, OVCA432, OVCAR4), (2) one growth fac-
tor (Caov3, OVCAR3), or (3) none of the tested growth 
factors (OV90). In general, OVCAR3 and OVCAR4 
showed the most similar patterns of sensitivity to the dif-
ferent growth factors. Most of these effects were modest, 
with only OVCA432 demonstrating increases in MMP2 
of greater than twofold after growth factor stimula-
tion. With respect to the individual growth factors, our 
results demonstrated that HB-EGF increased MMP2 lev-
els in OVCA432, OVCAR3 and OVCAR4, and NRG1β 
increased MMP2 expression in Caov4 and OVCA432. 
Similar to the results for migration (Figs. 1, 2), IGF1 did 
not significantly impact MMP2 expression in any of the 
Fig. 1 The effects of growth factors on collective migration of HGSOC cell lines. a Treatment with 10 ng/mL HB-EGF, NRG1β, IGF1, or HGF for 48 h 
impacted wound closure in a subset of HGSOC cell lines. Cells were stained with CellTracker Green, seeded to confluency, and wound area was 
measured at 0 and 48 h post-treatment. Data presented as the average ± SD, n = 3. *p < 0.05 compared to vehicle. b Representative images of the 
wounds at time = 0 and 48 h for each cell line and treatment condition. As expected, CellTracker Green intensity had decreased by 48 h, however, 
the edge of the wound could still be analyzed. Scale bar represents 500 μm
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HGSOC cells tested. HGF increased MMP2 in Caov4 and 
OVCAR4 but decreased levels in Caov3.
Tumor cell proliferation in response to growth factors 
varied across HGSOC cell lines
Elevated cell proliferation is associated with the advanced 
stages of HGSOC [13]. Therefore, we determined the 
percentage of cells in S-phase after treatment with vehi-
cle, HB-EGF, NRG1β, IGF1, or HGF (Fig.  4). Despite 
the extended length of time in serum-free media, all 
cell lines continued to proliferate robustly and appeared 
healthy. A range of baseline levels of proliferation was 
detected (16.8  % for Caov4 to 34.8  % for OVCAR4). 
We observed that HGSOC cell lines had significantly 
Fig. 2 The effects of growth factors on single cell migration of HGSOC cell lines. HGSOC cell lines were seeded in transwells with 10 ng/mL HB-EGF, 
NRG1β, IGF1, or HGF in the bottom compartment. Following 48 h, cells that had migrated through the transwell were stained with Calcein-AM and 
the relative fluorescence was measured. For every cell line, an MDA-MB-231 positive control was performed in parallel; fluorescence for these cells 
was at least fivefold higher than for the HGSOC conditions. Data presented as the average ± SD, n = 3. *p < 0.05 compared to vehicle
Fig. 3 Growth factor-induced changes in MMP2 expression of HGSOC cell lines. a Total baseline levels of active MMPs in conditioned media was 
determined to vary across the cell lines when assayed with a fluorogenic MMP substrate. b Treatment with 10 ng/mL HB-EGF, NRG1β, IGF1, or HGF 
for 24 h impacted MMP2 expression in a subset of HGSOC cell lines. Expression levels were measured by qRT-PCR and fold change was determined 
using concurrently assayed GAPDH levels. Data presented as the average ± SD, n = 3. *p < 0.05 compared to vehicle
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increased proliferation following treatment with (1) all of 
the growth factors (Caov3) or (2) a subset of the growth 
factors (Caov4, OV90, OVCA432, OVCAR3, OVCAR4). 
In contrast to migration and MMP2 expression, there 
were no cell lines insensitive to all four growth factors, 
although the effects on OV90 were modest. None of 
the members of the cell line panel demonstrated iden-
tical patterns of responsiveness; for example, despite 
comparable baseline proliferation rates, OV90 and 
OVCAR4 exhibited only small (<4 %) changes in prolif-
eration regardless of which growth factor was used while 
OVCA432 was strongly sensitive to several growth fac-
tors. Of the growth factors, the effects of NRG1β were 
the most widespread, with large increases in prolifera-
tion for Caov3, Caov4, OVCA432, and OVCAR3, a slight 
increase for OVCAR4, and a slight decrease for OV90. 
HB-EGF significantly induced proliferation for Caov3, 
Caov4, and OVCA432, and a slight decrease in prolifera-
tion in OVCAR4 was seen. IGF1 induced proliferation in 
Caov3, OVCA432, and OVCAR3, with a slight increase 
for OV90. Finally, HGF increased proliferation for Caov3 
and OVCAR3 with slight effects on Caov4 and OVCAR4.
VEGF secretion in response to growth factors varied 
across HGSOC cell lines
Production of VEGF by tumor cells and other cells in 
the microenvironment is essential for the development 
of new blood vessels to support tumor growth [32]; ves-
sels that arise from VEGF-induced angiogenesis are often 
leaky, which in HGSOC results in the accumulation of 
large volumes of ascites fluid [14, 15]. Here, we analyzed 
the concentration of VEGF in conditioned media from six 
HGSOC cell lines after 24 h of stimulation with vehicle, 
HB-EGF, NRG1β, IGF1, or HGF (Fig. 5). In the absence of 
Fig. 4 Baseline and growth factor-induced proliferation of HGSOC cell lines. a Baseline proliferation varied across the six HGSOC cell lines and treat-
ment with 10 ng/mL HB-EGF, NRG1β, IGF1, or HGF for 24 h induced proliferation in a subset of these cell lines. Proliferation was determined by Click-
iT EdU and flow cytometry. Data presented as the average ± SD, n = 3. *p < 0.05 compared to vehicle. b Representative flow cytometry histograms 
for each cell line-growth factor condition, with the percentage of EdU-positive cells (cells in S-phase) indicated
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exogenous stimulation, all six cell lines secreted detect-
able levels of VEGF. These baseline concentrations varied 
greatly across the cell lines (ranging from 76.5 pg/mL for 
Caov3 to 1105.6 pg/mL for OVCAR4). Following growth 
factor treatment, VEGF levels increased in response to 
either: (1) all four growth factors (Caov3, OVCAR3), (2) a 
subset of growth factors (OV90, OVCA432), or (3) none 
of the tested growth factors (Caov4, OVCAR4). Overall, 
Caov3 and OVCAR3 showed the most similar response 
profile, with similar fold increases in response to each of 
the four tested growth factors. In contrast to the other 
behaviors studied, OV90 was responsive to growth factor 
stimulation, with increases in VEGF in response to HB-
EGF, NRG1β, and IGF1. Among the growth factors, cells 
were most responsive to NRG1β, with increased levels of 
VEGF seen in Caov3, OV90, OVCA432, and OVCAR3. 
HB-EGF treatment induced VEGF secretion in Caov3, 
OV90 and OVCAR3; despite impacting unique receptor 
tyrosine kinase families, cells showed a similar sensitiv-
ity to IGF1 as they had to HB-EGF. HGF increased VEGF 
levels only in Caov3 and OVCAR3.
Principal component analysis suggested HGSOC cell 
response to growth factors is dependent on the cell line
To examine patterns in our data, principal component 
analysis (PCA) was performed on the growth factor-
induced effects on migration, MMP2 expression, prolif-
eration, and VEGF secretion. As seen in the scores plot 
(Fig.  6), cell lines clustered together more closely than 
growth factor treatments. Cell lines were primarily sep-
arated by principal component 1; for example, Caov4, 
OV90, and OVCAR4 were generally unresponsive to the 
selected growth factors and projected negatively along 
this axis, while Caov3 and OVCAR3 were generally sensi-
tive and projected along the positive axis. In contrast, all 
four growth factors were distributed across both princi-
pal component 1 and principal component 2.
We examined two potential reasons for this result. 
First, it is possible that the baseline behavior of the cells 
would influence the growth factor-induced response. 
For example, it is possible that cells with high basal pro-
duction would not be able to produce additional VEGF. 
However, OVCA432 had the second highest basal level 
of VEGF (587  pg/mL), but was exquisitely sensitive to 
NRG1β, and nearly quadrupled the amount of VEGF pro-
duced (2258 pg/mL, Fig. 5). Additionally, baseline migra-
tion levels of Caov3 and Caov4 were similar, but Caov3 
was substantially more responsive to HB-EGF (Fig.  1). 
Secondly, the level of the receptors for the selected 
growth factor could influence the activity of the network 
upon growth factor treatment. In some cases, baseline 
receptor levels (Additional file 1) could predict sensitivity 
to growth factor treatment. For example, OV90 had the 
second lowest level of ErbB3, the receptor for NRG1β, 
and was generally unresponsive to this growth factor 
(Figs. 1, 2, 3, 4). However, OV90 also had the highest lev-
els of IGF1R and was insensitive to IGF1; indeed, in most 
Fig. 5 The impact of growth factors on VEGF secretion by HGSOC cell lines. HGSOC cell lines secreted varying baseline levels of VEGF and treatment 
with 10 ng/mL HB-EGF, NRG1β, IGF1, or HGF induced VEGF secretion in a subset of these cell lines. VEGF levels were determined by ELISA. Data 
presented as the average ± SD, n = 3. *p < 0.05 compared to vehicle. Note different scales on the y-axes
Fig. 6 PCA of growth factor effects on HGSOC cell behaviors. Scores 
plot for the first two principal components of the analysis of growth 
factor-induced changes in HGSOC cell behavior. Each cell line-growth 
factor combination is represented by a color (for the HGSOC cell line) 
and symbol (for the growth factor: HB-EGF (plus), NRG1β (square), IGF1 
(circle), and HGF (triangle))
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cases there was no correlation between receptor level and 
growth factor response.
Discussion
In order to determine if HGSOC cell lines with genomic 
profiles similar to the TCGA database demonstrate het-
erogeneity similar to that seen clinically, we examined 
differences in baseline migration, MMP2 expression, 
proliferation and VEGF secretion, as well as responsive-
ness to HB-EGF, NRG1β, IGF1 and HGF. As most prior 
studies have utilized only one or two cell lines, compari-
sons of the baseline behaviors for these cell lines have not 
been previously reported. Additionally, only twelve of the 
120 growth factor-induced endpoints in this study have 
been examined before [20, 25, 33–38]. Similar to the het-
erogeneity observed between HGSOC tumors, our analy-
sis indicated that there was substantial variation between 
these cell lines, and PCA of the data set indicated that the 
cell behaviors were more strongly influenced by cell type 
than growth factor identity.
Our results indicated that each of four tested growth 
factors impacted several behaviors across the cell line 
panel. Of the 24 different cell line-endpoint combina-
tions, HB-EGF and NRG1β significantly increased 14 
endpoints and HGF increased 12 endpoints (each of 
these growth factors also resulted in one behavior that 
was slightly decreased). While the results were generally 
consistent with previous reports for the members of the 
cell panel [20, 25, 34, 36, 37] there were some noted dif-
ferences relative to prior studies with SKOV3. For exam-
ple, IGF1 did not stimulate migration in either of the 
assays, but has been shown to increase wound closure for 
SKOV3 [39]. Likewise, HGF had no effect on any cell line 
in the transwell assay but has been repeatedly shown to 
induce chemotactic migration in SKOV3 [38, 40, 41]. The 
diverse effects of the growth factors suggest that target-
ing one growth factor pathway will not be sufficient to 
abrogate tumor cell behavior and may help explain the 
inefficacy of receptor-targeted therapies in ovarian can-
cer [42–45]. One notable exception to this trend has been 
the promising results from clinical trials with anti-ErbB3 
antibodies [46–48]. NRG1β stimulated proliferation and 
VEGF secretion in multiple cell lines suggesting this 
approach may successfully target multiple mechanisms in 
a larger population of patients.
Of the individual cellular behaviors examined, the 
selected growth factors had the strongest effect on pro-
liferation, with three or more cell lines sensitive to each 
growth factor, and VEGF secretion, where each growth 
factor impacted at least two cell lines. This may of course 
result from the high sensitivity and precision of these 
assays and highlights the importance of considering assay 
choice when doing in vitro studies. The impact of assay 
choice was further exemplified by the striking differ-
ences observed between the wound and transwell assays 
for migration. While both assays are commonly used to 
measure cell migration, they examine different biologi-
cal mechanisms as wound assays monitor collective cell 
migration and transwell assays assess single cell motility 
in response to chemotactic stimuli. Our results indicated 
that growth factors have a substantially stronger effect 
on collective migration versus single cell migration in the 
HGSOC cell lines. In addition, the effects of growth fac-
tor treatment on MMP2 levels did not mirror the effects 
seen for migration, suggesting that unique therapeu-
tic strategies may be required to control these different 
mechanisms of HGSOC metastasis.
It is of course important to compare our in vitro find-
ings to data from clinical samples in order to determine 
if these cell lines that are representative of the HGSOC 
genotype [6] are also representative of its phenotype. The 
growth factors examined in this study have been previ-
ously suggested to have a role in HGSOC, are expressed 
in a high percentage of tumors, and are generally elevated 
compared to normal tissue [20, 49–53]. All growth fac-
tors were examined at a dose of 10  ng/mL, reflecting 
the concentrations reported for HB-EGF and HGF in 
ascites fluid of ovarian cancer patients [52, 54]. All cell 
lines proliferated when treated with vehicle; however, the 
extent of proliferation varied depending on the cell line 
(16.8–34.8 %). This spread was consistent with variation 
observed in proliferation in primary tumors (0.4–23.04 % 
[55]), although the absolute levels were higher. Addition-
ally, all cell lines secreted detectable levels of VEGF in 
culture (76.5–1105.6 pg/mL), which was consistent with 
reports of serum levels in HGSOC (92–721 pg/mL [56]). 
MMPs are often expressed in HGSOC [57, 58]; thus, it 
was not surprising that all cell lines secreted detectable 
levels of MMPs. While it is not possible to directly relate 
these levels to reports from primary tumors, MMP lev-
els varied between the examined lines and immunohis-
tochemistry for MMP2 also showed variation between 
HGSOC samples [59].
Finally, even though a growth factor was capable of 
impacting a cell behavior in one cell line, there was no 
guarantee that it would impact another cell line, even if 
that other cell line was sensitive with respect to a differ-
ent endpoint. For example, HB-EGF induced prolifera-
tion and migration in Caov3 but only proliferation for 
OVCA432. This is reflected in the clustering by cell type 
rather than growth factor in PCA. However, neither base-
line cellular behaviors nor growth factor receptor levels 
were predictive of sensitivity. It is possible that variations 
in the levels of other components of the cellular signal-
ing network besides growth factor receptors could be 
responsible for the observed heterogeneity. For example, 
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it has been shown that when predicting cell response, 
dimerization patterns of ErbB1 with other ErbB recep-
tors is important to consider [60], as is the ratio of IGF1 
to IGF1R and the level of the IGF binding proteins [61]. 
Likewise, previous work from our lab demonstrated 
that it was necessary to incorporate the levels of both 
ligands and receptors when predicting ovarian cancer cell 
response to an ErbB-targeted inhibitor [62]. Ultimately, 
our analysis demonstrated that these six cell line models 
of HGSOC exhibit heterogeneity consistent with the dis-
ease. Our results also highlight the difficulty in develop-
ing targeted therapies for HGSOC since determining the 
target that will halt metastatic spread will not be as direct 
as simply identifying the growth factors or receptors pre-
sent at the highest levels.
Methods
Cell lines and culture methods
Caov3 (HTB-75), Caov4 (HTB-76), OV90 (CRL-11732), 
OVCAR3 (HTB-161), and MDA-MB-231 were pur-
chased from American Type Culture Collection (ATCC; 
Rockville, MD). OVCA432 [63] were obtained from 
Dr. R. Bast (MD Anderson Cancer Center; Houston, 
TX, USA). OVCAR4 [64] were obtained from the NCI 
Tumor Repository (Frederick, MD). HGSOC cell lines 
were authenticated by human short tandem repeat 
(STR) analysis at the Translational Research Initiatives 
in Pathology (TRIP) lab at the University of Wiscon-
sin–Madison. Briefly, the analysis was conducted utiliz-
ing the Promega® 16 HS reagent system, multiplex PCR 
amplification, capillary electrophoresis (ABI 3500) and 
GeneMapper (v.4.1) software. All HGSOC cell lines are 
reported to possess a mutation in TP53 (Table  1). Cells 
were maintained at 37 °C in a humidified 5 % CO2 atmos-
phere. Caov3, Caov4, OV90, OVCA432, OVCAR4, and 
MDA-MB-231 were cultured in a 1:1 (v/v) ratio of MCDB 
105 (Sigma-Aldrich; St. Louis, MO, USA) and Medium 
199 (Corning; Corning, NY, USA) supplemented with 1 % 
penicillin/streptomycin (Life Technologies; Grand Island, 
NY, USA) and 10 % heat-inactivated fetal bovine serum 
(Life Technologies). OVCAR3 cells were cultured in 
RPMI 1640 (Corning) supplemented with 20 % heat-inac-
tivated fetal bovine serum, 1  % penicillin/streptomycin, 
1  % sodium pyruvate (Sigma), 0.3  % glucose (Corning), 
and 10 ng/mL insulin (Sigma).
Tumor cell migration
For wound assays, HGSOC cells were stained with 
5 μM CellTracker™ Green CMFDA Dye (Life Technolo-
gies), plated in 48-well plates at cell densities empirically 
determined to result in 100  % confluency, and allowed 
to attach overnight. Specifically, Caov3, Caov4, and 
OV90 were plated at 132,000 cells/cm2, OVCA432 and 
OVCAR3 at 105,000 cells/cm2, and OVCAR4 at 121,000 
cells/cm2. Cells were then rinsed with PBS and serum-
free media was added. After serum starving for 24  h, a 
scratch was made in each well with a 200 μL pipette tip, 
cells were washed twice with serum-free media, and the 
wound was imaged with an Olympus IX51 Fluorescent 
Microscope (Olympus America Inc.; Center Valley, PA, 
USA). Cells were then treated with vehicle (0.1 % BSA in 
PBS) or 10 ng/mL recombinant human HB-EGF, NRG1β, 
IGF1, or HGF (Peprotech; Rocky Hill, NJ, USA) in serum-
free media. Forty-eight hours post-treatment, the wound 
was imaged again, and the percent wound closure was 
measured using ImageJ (NIH; Bethesda, MD, USA).
Transwell assays were performed using polycarbonate 
Transwell® inserts (#3422, Corning) with 8  μm pores. 
HGSOC cells were serum starved for 24  h, dissoci-
ated using TrypLE Select Enzyme (Life Technologies), 
and 150,000 cells/well were seeded in serum free media 
in the top compartments of the transwells inserted in 
24-well plates. The bottom compartments contained 500 
μL serum free media plus vehicle (0.1 % BSA in PBS) or 
10  ng/mL HB-EGF, NRG1β, IGF1, or HGF. All experi-
ments included a positive control of the highly invasive 
MDA-MB-231 breast cancer cell line [65] in the top 
compartment and 10  % serum-containing media in the 
bottom compartment. After 48 h of treatment, any cells 
which had migrated through the transwell into the bot-
tom compartment were dissociated and stained for 
30 min at 37 °C with 400 μL of a 4 μM Calcein AM (Life 
Technologies)/TrypLE dissociation solution. After disso-
ciation and staining, 100 μL of each well was transferred 
to a black-walled, 96-well plate (Corning) and analyzed at 
485 nm excitation and 520 nm emission using a Fluoros-
kan Ascent™ Microplate Fluorometer (Thermo Scientific; 
Waltham, MA, USA).
MMP characterization
To characterize total levels of active MMPs, HGSOC 
cells were plated in 12-well plates at cell densities empiri-
cally determined to result in approximately 70  % con-
fluency and allowed to attach overnight. Specifically, 
Table 1 TP53 mutation status of  HGSOC cell lines utilized 
in this study
Cell line TP53 mutation
Caov3 406 C > T—Nonsense (Q136X) [6, 67, 68]
Caov4 440 T > A—Missense (V147D) [6, 67, 68]
OV90 643 A > C—Missense (S215R) [6, 67, 69]
OVCA432 830 G > T—Missense (C277F) [67, 70, 71]
OVCAR3 743 G > A—Missense (R248Q) [6, 70–73]
OVCAR4 388 C > G—Missense (L130 V) [6]
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Caov3, Caov4, and OV90 were plated at 29,000 cells/
cm2, OVCA432 and OVCAR3 at 24,000 cells/cm2, and 
OVCAR4 at 26,000 cells/cm2. Cells were then rinsed 
with PBS and serum-free media was added. After 48 h of 
serum starvation, conditioned media was collected and 
assayed at a 1:1 (v/v) ratio with 20 μM Mca-PLGL-Dpa-
AR-NH2 fluorogenic MMP substrate (R&D Systems: 
Minneapolis, MN) in 96-well, black-walled plates. After a 
24 h incubation at 37 °C, MMP activity was measured by 
quantifying fluorescent intensity at an excitation/emis-
sion of 320/405 nm. To determine the impact of growth 
factors on MMP2 expression, cells were plated in 6-well 
plates at the same cell densities as the total MMP assay. 
After overnight attachment, cells were washed with PBS 
and serum-free media was added. Following 24  h of 
serum starvation, cells were washed with PBS and vehi-
cle (0.1  % BSA in PBS) or 10  ng/mL HB-EGF, NRG1β, 
IGF1, or HGF was added in serum-free media. After 24 h 
of growth factor treatment, mRNA was isolated using 
the RNeasy Mini Kit (Qiagen; Hilden, Germany) accord-
ing to manufacturer’s instructions and quantified on a 
NanoDrop 2000 Spectrophotometer (Thermo Scientific 
Pierce). cDNA was synthesized from 1  μg RNA using 
the Superscript III First-Strand Synthesis System kit 
(Life Technologies) according to manufacturer’s instruc-
tions. qRT-PCR was performed on 100  ng cDNA using 
SYBR Green PCR Master Mix (Life Technologies) and 
QuantiTect primers for MMP2 (QT00088396, Qiagen) 
or GAPDH (QT00079247, Qiagen). The fold change in 
gene expression of MMP2 was determined by the ΔΔCt 
method relative to GAPDH expression.
Tumor cell proliferation
HGSOC cells were plated in 12-well plates at the same 
cell densities as the MMP2 expression assay and allowed 
to attach overnight. Cells were then rinsed with PBS 
and serum-free media was added. After serum starv-
ing for 24 h, cells were washed with PBS and stimulated 
with vehicle (0.1  % BSA in PBS) or 10  ng/mL HB-EGF, 
NRG1β, IGF1, or HGF in serum-free media. After 24  h 
of treatment, cell proliferation was quantified using the 
Click-iT® EdU Alexa Fluor® 488 flow cytometry assay 
(Life Technologies) according to manufacturer’s instruc-
tions. Cells were incubated with EdU for 6  h prior to 
sample collection and analyzed on a BD Accuri™ C6 flow 
cytometer (BD; Franklin Lakes, NJ, USA). Samples were 
gated for the EdU-positive population to determine the 
percentage of cells that entered S-phase during the EdU 
incubation.
VEGF secretion
HGSOC cells were plated in 12-well plates at the same 
cell densities as the MMP2 expression assay and allowed 
to attach overnight. Cells were then rinsed with PBS and 
serum-free media was added. After serum starving for 
24 h, cells were washed with PBS and vehicle (0.1 % BSA 
in PBS) or 10 ng/mL HB-EGF, NRG1β, IGF1, or HGF was 
added in serum-free media. After 24 h of growth factor 
treatment, conditioned media was collected, and VEGF 
levels were determined by ELISA (#DY293B, R&D Sys-
tems) according to the manufacturer’s instructions.
Principal component analysis
Principal component analysis (PCA, [66]) was performed 
on the resulting data matrix (composed of rows for each 
cell line-growth factor combination and columns of the 
levels of growth factor-induced response relative to 
vehicle-treated controls—i.e., percent increase in prolif-
eration, percent increase in wound closure, fold change 
in fluorescence for transwell migration, fold change in 
MMP2, fold change in VEGF). The first principal compo-
nent captured 47.0 % of the variation; inclusion of a sec-
ond principal component increased this to 74.7 %. PCA 
was performed using SIMCA.P + v.12.0.1 (Umetrics; San 
Jose, CA, USA) with mean-centered and variance-scaled 
data.
Statistical analysis
All data are presented as the mean ± standard deviation 
(n = 3). Additionally, all experiments were performed at 
least twice to ensure reproducibility. Statistical signifi-
cance was determined using Dunnett’s with vehicle sam-
ples set as the control. All statistical calculations were 
performed with JMP 4.1 software (SAS Institute; Cary, 
NC, USA), with statistical significance set as p < 0.05.
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